Related Experiment Videos
[Treatment of eye burns with a polyvalent proteolytic inhibitor]
R A Gundorowa1, G G Bordjugowa, I P Choroschilowa-Maslewa
1Helmholtzinstitut für Ophthalmologie, Moskau, UDSSR.
Abstract:
The present paper reports the results of a study on the use of a polyvalent proteolysis inhibitor (Gordox), the active agent of which is aprotinin, in early stages of ocular burn injuries. Following experimental corneal burns, Gordox influenced the activity of proteolytic enzymes in ocular tissue and morphologic changes in the cornea. Various administration methods were studied--instillation, and subconjunctival and intravenous injection. The preparation reduced the activity of proteolytic enzymes in the burned region of the cornea by a factor of two and led to "stages" in healing processes, thus preventing severe complications following ocular burns. In 98 patients (152 eyes) with ocular burn injuries, Gordox was found to be highly efficacious: in particular, it reduced the severity of inflammation in ocular tissues and considerably decreased the incidence of corneal perforations.
Insights
Aprotinin (Gordox) effectively treats ocular burns by reducing proteolytic enzyme activity and inflammation. This study shows it prevents severe complications like corneal perforations in patients.
Area of Science:
- Ophthalmology
- Biochemistry
- Pharmacology
Context:
- Ocular burn injuries present significant challenges in early management.
- Proteolytic enzymes play a critical role in tissue damage following burns.
- Current treatment strategies aim to mitigate inflammation and prevent secondary complications.
Purpose:
- To evaluate the efficacy of a polyvalent proteolysis inhibitor, aprotinin (Gordox), in managing early-stage ocular burn injuries.
- To investigate the effects of Gordox on proteolytic enzyme activity and corneal morphology.
- To compare different administration routes for Gordox in ocular burn treatment.
Summary:
- The study investigated aprotinin (Gordox) for experimental corneal burns, observing its impact on proteolytic enzyme activity and corneal morphology.
- Different administration methods (instillation, subconjunctival, intravenous) were assessed.
- Gordox demonstrated a twofold reduction in proteolytic enzyme activity in burned corneal tissue, promoting staged healing and preventing severe complications.
Impact:
- Gordox treatment in 98 patients (152 eyes) with ocular burns showed high efficacy.
- The inhibitor significantly reduced ocular tissue inflammation.
- A notable decrease in the incidence of corneal perforations was observed, highlighting its therapeutic potential.